The US Food and Drug Administration (FDA) has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib for the treatment of adults with severe alopecia areata. The development, which was announced in a July 25, 2024, news release from the drug’s manufacturer Sun Pharma, is based on data from two pivotal randomized, double-blind, placebo-controlled phase 3...
Tag: <span>Alopecia Areata</span>
Post
Alopecia Areata Linked to Psychiatric, Autoimmune Comorbidities
Medscape Medical News > MedBrief Edited by Shrabasti Bhattacharya August 01, 2024 TOPLINE:Patients with alopecia areata (AA) had a higher prevalence of several psychiatric and autoimmune comorbidities at baseline and were at greater risk of developing those comorbidities after diagnosis. METHODOLOGY:Researchers evaluated 63,384 patients with AA and 3,309,107 individuals without AA (aged 12-64 years) from...